Great Valley Advisor Group’s Summit Therapeutics SMMT Stock Holding History

Great Valley Advisor Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$377K	Buy	25,840 +200	+0.8%	+$3.55K	0.01%	804
2026 Q1	$486K	Hold	25,640	–	–	0.01%	696
2025 Q4	$448K	Sell	25,640 -33	-0.1%	-$621	0.01%	656
2025 Q3	$530K	Buy	25,673 +500	+2%	+$12.1K	0.01%	615
2025 Q2	$536K	Buy	25,173 +40	+0.2%	+$912	0.01%	585
2025 Q1	$485K	Buy	25,133 +32	+0.1%	+$642	0.01%	593
2024 Q4	$448K	Buy	25,101 +101	+0.4%	+$1.96K	0.01%	598
2024 Q3	$548K	Sell	25,000 -9,023	-27%	-$126K	0.01%	543
2024 Q2	$265K	Hold	34,023	–	–	0.01%	672
2024 Q1	$141K	Hold	34,023	–	–	﹤0.01%	724
2023 Q4	$88.8K	Hold	34,023	–	–	﹤0.01%	692
2023 Q3	$63.6K	Hold	34,023	–	–	﹤0.01%	659
2023 Q2	$85.4K	Hold	34,023	–	–	﹤0.01%	685
2023 Q1	$59.5K	Buy	+34,023	New	+$92.8K	﹤0.01%	683

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Great Valley Advisor Group's SMMT Position: Q2 2026 in Review

Great Valley Advisor Group increased its Summit Therapeutics (SMMT) stake by 0.78% in Q2 2026, buying an estimated $3.55K and bringing the position to 25,840 shares worth $377K. The position accounts for 0.01% of the portfolio, ranked #804.

Great Valley Advisor Group first reported a position in SMMT in Q1 2023 and has held it in 14 quarters since. The position peaked at $548K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Great Valley Advisor Group held 25,840 shares of Summit Therapeutics worth $377K as of Q2 2026.
Great Valley Advisor Group bought 200 Summit Therapeutics shares in Q2 2026, an estimated $3.55K.
Summit Therapeutics made up 0.01% of Great Valley Advisor Group's portfolio in Q2 2026, its #804 holding.
Great Valley Advisor Group first reported a position in Summit Therapeutics in Q1 2023 and has held it in 14 quarters since.
Great Valley Advisor Group's Summit Therapeutics position peaked at $548K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.